SEVERINO MICHAEL 4
4 · AbbVie Inc. · Filed May 18, 2022
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
SEVERINO MICHAEL
EVP, R&D and CSO
Transactions
- Exercise/Conversion
Common Stock, $0.01 par value
2022-05-16$79.02/sh+29,121$2,301,141→ 252,103 total - Exercise/Conversion
Common Stock, $0.01 par value
2022-05-16$61.36/sh+70,879$4,349,135→ 222,982 total - Sale
Common Stock, $0.01 par value
2022-05-16$154.80/sh−53,327$8,255,020→ 152,503 total - Sale
Common Stock, $0.01 par value
2022-05-16$154.04/sh−46,273$7,127,893→ 205,830 total - Sale
Common Stock, $0.01 par value
2022-05-16$155.44/sh−400$62,176→ 152,103 total - Exercise/Conversion
Common Stock, $0.01 par value
2022-05-17$79.02/sh+35,364$2,794,463→ 187,467 total - Exercise/Conversion
Common Stock, $0.01 par value
2022-05-17$93.50/sh+64,636$6,043,466→ 252,103 total - Sale
Common Stock, $0.01 par value
2022-05-17$153.43/sh−43,621$6,692,770→ 208,482 total - Sale
Common Stock, $0.01 par value
2022-05-17$154.49/sh−54,279$8,385,563→ 154,203 total - Sale
Common Stock, $0.01 par value
2022-05-17$155.27/sh−2,100$326,067→ 152,103 total - Exercise/Conversion
Option (Right to Buy)
2022-05-16$61.36/sh−70,879$4,349,135→ 0 totalExercise: $61.36From: 2018-02-16Exp: 2027-02-15→ Common Stock (70,879 underlying) - Exercise/Conversion
Option (Right to Buy)
2022-05-16$79.20/sh−29,121$2,306,383→ 35,364 totalExercise: $79.02From: 2020-02-21Exp: 2029-02-20→ Common Stock (29,121 underlying) - Exercise/Conversion
Option (Right to Buy)
2022-05-17$79.02/sh−35,364$2,794,463→ 0 totalExercise: $79.02From: 2020-02-21Exp: 2029-02-20→ Common Stock (35,364 underlying) - Exercise/Conversion
Option (Right to Buy)
2022-05-17$93.50/sh−64,636$6,043,466→ 49,930 totalExercise: $93.50From: 2021-02-20Exp: 2030-02-19→ Common Stock (64,636 underlying)
Footnotes (7)
- [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.38 to $154.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.38 to $154.81 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.44. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.95 to $153.92 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.02 to $155.00 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.27. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.